CN114591917B

CN114591917B - Hybridoma cells producing antibodies that bind beta-amyloid and uses thereof

Info

Publication number: CN114591917B
Application number: CN202210490680.4A
Authority: CN
Inventors: 张博文; 康志云; 王怡; 郑新越; 杨志云; 李晓英; 王月丹; 王铁山
Original assignee: Beijing First Biochemical Pharmaceutical Co ltd
Current assignee: Beijing First Biochemical Pharmaceutical Co ltd
Priority date: 2022-05-07
Filing date: 2022-05-07
Publication date: 2022-09-02
Anticipated expiration: 2042-05-07
Also published as: CN114591917A

Abstract

The application provides a hybridoma cell strain for generating a monoclonal antibody specifically binding to beta-amyloid and application thereof. The anti-amyloid-beta monoclonal antibodies produced by the hybridoma cells of the present application are capable of specifically binding to primate-amyloid-beta, preferably with a high affinity effect on human-amyloid-beta. The hybridoma cells producing the monoclonal antibodies that specifically bind to beta-amyloid and the monoclonal antibodies produced by the hybridoma cells can be used for detecting beta-amyloid and/or for diagnosing Alzheimer's disease.

Description

Hybridoma cells producing antibodies that bind beta-amyloid and uses thereof

Technical Field

The present application relates to the field of cells and antibodies, and more particularly, to hybridoma cells producing monoclonal antibodies against beta-amyloid and uses thereof.

Background

Alzheimer's Disease (AD) is a progressive neurological Disease that impairs thinking, memory and independence, leading to early infancy, which is currently not prevented, delayed or prevented, creating an increasingly serious global health crisis. The preclinical stage involves all invisible changes in the brain (such as plaque accumulation) occurring years before symptoms appear, with the development of disease and the increasing need for patient care in daily activities, mild AD patients can still take care of their lives despite beginning to forget the location of familiar words or objects; progressing to moderate, patients become more forgetful, more difficult to perform routine tasks, and experience changes in personality and behavior; patients with severe AD can no longer respond to their environment, can not talk, and can not control exercise or control stool.

The etiology of AD is still unclear, and the Amyloid beta peptide (a β) cascade hypothesis suggests that oligomers and fibers formed by aggregation and unbalanced metabolism of a β protein may be deposited in the brain, and the deposits form senile plaques, which cause brain lesions such as neuritis increase and neuronal apoptosis, and are important factors for inducing alzheimer's disease. A β has a molecular weight of about 4kDa, is a neurotoxic protein produced by twice cleavage of transmembrane Amyloid Precursor Protein (APP) by β and γ secretases, is formed by protein misfolding, can exist as monomers, oligomers, fibrils and insoluble fibers, deposits in the brain with synaptic damage and neuronal death.

Although there is no cure for AD, some FDA-approved drugs, such as cholinesterase inhibitors (increasing the amount of the neurotransmitter acetylcholine in the brain, promoting intercellular signaling), NMDA receptor antagonists (altering brain cell signaling), can delay disease progression, but these drugs still have inadequate efficacy, especially in moderate to severe AD patients, and still fail to meet the clinical needs of the patients. In addition, some drugs, while sometimes delaying the mental decline of some patients, can cause serious side effects. Therefore, patients need more effective drugs.

In recent years, research on treating AD by taking Abeta as a drug target has been greatly advanced, and in 7/6/2021, the American Food and Drug Administration (FDA) announces approval of a Bohai Jian (Biogen) company to develop a new Alzheimer disease drug, namely, Aducantamab (Aducanumab, trade name Aduhelm), on the market. Adalimumab represents the first approved treatment for alzheimer's disease with the most common adverse effects (at least 10% higher than placebo incidence): ARIA edema, headache, ARIA-H micro-bleeding, ARIA-H surface iron deposition and falls.

Studies have shown that immunotherapy designed to remove a β from the brain has produced positive results in animal models of AD, and thus detection of a β protein is of great importance for the diagnosis, intervention and treatment of AD.

Therefore, the development of A beta (particularly A beta 1-42 peptide and/or A beta 1-40 peptide) targeting antibodies has certain significance for laboratory research and clinical diagnosis of AD.

Disclosure of Invention

In a first aspect, the present application provides a hybridoma cell line producing a monoclonal antibody that specifically binds to beta-amyloid, which is deposited under the accession number of CGMCC number 45042.

In some embodiments of the first aspect, the hybridoma cell line is designated 6C8-1B 9.

In some embodiments of the first aspect, the hybridoma cell line is a mouse hybridoma cell line, for example a Balb/c mouse hybridoma cell line.

In some embodiments of the first aspect, the monoclonal antibody specifically binds to primate beta-amyloid. In some embodiments of the first aspect, the monoclonal antibody specifically binds to human β -amyloid.

In some embodiments of the first aspect, the monoclonal antibody specifically binds to the A β 1-40 subtype or the A β 1-42 subtype of human β -amyloid. In some embodiments of the first aspect, the monoclonal antibody specifically binds to the A β 1-42 subtype of human β -amyloid.

In some embodiments of the first aspect, the monoclonal antibody comprises a heavy chain constant region selected from the group consisting of an IgG1 subtype, an IgG2 subtype, and an IgG4 subtype.

In some embodiments of the first aspect, the monoclonal antibody comprises a light chain constant region selected from the kappa subtype or the lambda subtype.

In some embodiments of the first aspect, wherein the EC of said monoclonal antibody ₅₀ The value does not exceed 100 pM.

In a second aspect, the present application provides a monoclonal antibody that specifically binds to amyloid beta, produced by the hybridoma cell line of the first aspect.

In a third aspect, the present application provides a method for producing the monoclonal antibody of the second aspect, which comprises culturing the hybridoma cell line of the first aspect.

In some embodiments of the third aspect, the method further comprises the step of purifying the monoclonal antibody.

In a fourth aspect, the application provides a hybridoma cell line of the first aspect or a monoclonal antibody of the second aspect for use in preparing a product for detecting beta-amyloid and/or diagnosing alzheimer's disease.

Drawings

FIG. 1 shows the EC of monoclonal antibodies produced by hybridoma cell line 6C8-1B9 ₅₀ Value determination curves.

FIG. 2 shows the results of subtype detection of the monoclonal antibody produced by hybridoma cell line 6C8-1B 9.

Detailed Description

The most common subtypes of A beta in a human body are A beta 1-40 and A beta 1-42, in human cerebrospinal fluid and blood, the content level of the A beta 1-40 is 10 times and 1.5 times higher than that of the A beta 1-42 respectively, and the A beta 1-42 has stronger toxicity and is easier to aggregate, so that a core of A beta precipitation is formed, and neurotoxicity effect is caused. Under pathological conditions, the generation of A beta in the brain of an AD patient is 4-10 times that of the AD patient under normal conditions, a large amount of A beta is gathered to form neuritic plaques (senile plaques), and the formation of the senile plaques causes the death of a large amount of cells in the hippocampus, so that the two prolonged amino acids not only increase the hydrophobicity of the A beta and enable the A beta to be more easily gathered, but also improve the stability of the aggregates, and the A beta can be selectively deposited in amyloid plaques at an early stage.

In AD patients, changes in the concentration of a β occur in the cerebrospinal fluid (CSF), the pathological changes of which are, in turn, brain a β accumulation, increased CSF, decreased hippocampal and gray matter volume, decreased glucose metabolism, memory impairment and dementia. A β can be produced by a variety of cells, circulating in the blood, cerebrospinal fluid and brain interstitial fluid, mostly bound to chaperone molecules, and a few in a free state. A β is expressed not only in brain cells but also in neurons, astrocytes and microglia, and also in peripheral organs and tissues such as liver, kidney, pancreas, spleen and other organs, and various blood and endothelial cells.

The A beta antibody can depolymerize in vitro aggregated A beta, so that the toxic effect of the A beta antibody is reduced, and when the A beta antibody is used for treating a transgenic AD mouse, the number of senile plaques in the brain of a model mouse can be reduced, and the learning and memory capacity of the mouse can also be improved, so that the preparation and application of the antibody aiming at the A beta and different fragments thereof have positive influence on the diagnosis, treatment and research of related diseases.

The application provides hybridoma cell lines that produce monoclonal antibodies that specifically bind to beta-amyloid. The hybridoma cell strain can produce a monoclonal antibody specifically binding to the beta-amyloid protein. In a preferred embodiment, the hybridoma cell lines of the present application produce monoclonal antibodies that specifically bind to beta-amyloid with an EC of the order of pM ₅₀ The value is obtained. The application also provides a method for generating the monoclonal antibody specifically binding to the beta-amyloid, and medical and biological applications of the hybridoma cell strain and the monoclonal antibody generated by the hybridoma cell strain, such as detection of beta-amyloid level and/or diagnosis of Alzheimer's disease.

To facilitate understanding of the present application, certain terms used herein are first defined.

As used herein, the term "hybridoma cell" refers to a cell obtained by fusing myeloma cells and B lymphocytes in the course of preparing a monoclonal antibody. Hybridoma cells are typically prepared by culturing neoplastic cells, which allow the nucleus of two different sources to function in the same cell.

As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, e.g., binding of an antibody to an epitope of an antigen, e.g., the ability of an antibody to bind to a specific antigen with at least two times greater affinity than its affinity for a non-specific antigen. It will be appreciated, however, that an antibody is capable of specifically binding to two or more antigens associated with its sequence. For example, a monoclonal antibody of the invention can specifically bind to beta-amyloid in humans and non-humans (e.g., mice or non-human primates).

As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations in a small number of individuals.

As used herein, the term "homology" is defined as the percentage of residues in an amino acid or nucleotide sequence variant that are identical, if necessary to the maximum percentage, after alignment and the introduction of gaps in the sequence. Methods and computer programs for alignment are well known in the art. As used herein, "at least 80% homology" means any value of 80% to 100% homology, e.g., 85%, 90%, 95%, 99%, etc.

As used herein, the term "EC ₅₀ The value "means the half maximal Effect Concentration (EC) of 50% of the maximum effect ₅₀ ) And refers to the concentration that causes 50% of the maximum effect.

In a first aspect, the application provides a hybridoma cell strain for producing a monoclonal antibody specifically binding to beta-amyloid, which is preserved in China general microbiological culture Collection center (CGMCC) with a preservation number of CGMCC number 45042 and a preservation date of 2022 years, 2 months and 17 days.

In some embodiments of the first aspect, the antibodies and/or antibody-producing cells are obtained from within the animal after the animal has been vaccinated with the beta-amyloid (e.g., subtype A β 1-42) antigen. Antibody-producing immortalized cell lines can be prepared from cells isolated from immunized animals. Following immunization, the animal is killed, lymph node and/or spleen B cells are immortalized, treated with an oncogenic compound and a mutagenic compound, and fused with immortalized cells (e.g., myeloma cells) to inactivate tumor suppressor genes. When myeloma cells are used for fusion, the myeloma cells preferably do not secrete immunoglobulin polypeptides (non-secreting cell lines). Screening of immortalized cells using beta-amyloid, a portion thereof or cells expressing beta-amyloid. In a preferred embodiment, the primary screening is performed using enzyme-linked immunosorbent assay (ELISA). Cells, such as hybridomas, that produce anti-beta-amyloid antibodies are selected for cloning and further screened for desired characteristics, including good growth, high antibody production, and desirable antibody characteristics. Methods for screening, cloning and amplifying hybridomas are well known to those of ordinary skill in the art. In some embodiments of the first aspect, the immunized animal is a non-human animal, wherein the splenic B cells are fused to a myeloma cell line from the same species as the non-human animal. In some embodiments of the first aspect, the immunized animal is a Balb/c mouse.

The monoclonal antibody produced by the hybridoma cell of the first aspect disclosed herein is capable of specifically binding to beta-amyloid. In some embodiments of the first aspect, the anti-monoclonal antibody specifically binds to primate beta-amyloid, or beta-amyloid of a species having high homology to primate beta-amyloid. In some specific embodiments of the first aspect, the monoclonal antibody specifically binds to human beta-amyloid, e.g., the A beta 1-40 subtype or the A beta 1-42 subtype of human beta-amyloid, preferably the A beta 1-42 subtype.

In some embodiments of the first aspect, the heavy chain constant region is of the IgG2 subtype.

In some embodiments of the first aspect, the heavy chain constant region is an IgG2b subtype.

In some embodiments of the first aspect, the light chain constant region is of the kappa subtype.

In some embodiments of the first aspect, the EC of a monoclonal antibody produced by a hybridoma cell of the present application ₅₀ The value does not exceed 100 pM. In some embodiments of the first aspect, the EC of the monoclonal antibody ₅₀ The values were 15 pM to 50 pM. In some embodiments of the first aspect, the EC of the monoclonal antibody ₅₀ The value was 15 pM to 35 pM. In some embodiments of the first aspect, the EC of the monoclonal antibody ₅₀ The value was 30.58 pM.

In some more specific embodiments, the antibodies disclosed herein are anti-human β -amyloid monoclonal antibodies. The type and subtype of amyloid-beta antibody can be determined by any means known in the art. Generally, antibody types and subtypes can be determined using antibodies specific for a particular antibody type and subtype.

In some embodiments of the third aspect, the anti-amyloid beta antibody disclosed herein may be isolated and purified using affinity chromatography, and depending on the nature of the affinity column utilized, the anti-amyloid beta antibody bound to the affinity column may be eluted using conventional methods, such as high salt buffers, pH changes, and the like.

In some embodiments of the third aspect, the purification of the monoclonal antibody may be performed using a Protein G affinity chromatography column.

In a fourth aspect, the present application provides a hybridoma cell line or an antigen binding portion thereof according to the first aspect or a monoclonal antibody according to the second aspect for use in preparation of a product for detecting β -amyloid and/or diagnosing alzheimer's disease.

In some embodiments of the fourth aspect, the product can be a kit, a test strip (e.g., a colloidal gold immunochromatographic test strip), a test card, a microfluidic test device, or the like.

In some embodiments of the fourth aspect, the product may further comprise a detectable label, such as colloidal gold, a chemiluminescent label, a fluorescent label, a nanoparticle label, and the like.

In some embodiments of the fourth aspect, the product may also include other reagents for detection, such as enzyme or colloidal gold labeled antigens or antibodies, substrates, reference standards, dilutions, washing solutions, and the like.

In some embodiments of the fourth aspect, the product may further comprise reagents for processing a biological sample for detection, which may be cerebrospinal fluid, brain interstitial fluid, urine, blood or serum.

In some embodiments of the fourth aspect, the product may further comprise product instructions for use.

In the present description and claims, the words "comprise", "comprises" and "comprising" mean "including but not limited to", and are not intended to exclude other moieties, additives, components or steps.

It should be understood that features, characteristics, components or steps described in a particular aspect, embodiment or example of the present application may be applied to any other aspect, embodiment or example described herein unless incompatible therewith.

The above disclosure generally describes the present application and the following examples are further illustrative of the present application and are not to be construed as limiting the present application. The invention discloses a hybridoma cell strain capable of generating a monoclonal antibody specifically binding beta-amyloid (A beta 1-42 subtype) of primates (human beings and the like), a monoclonal antibody specifically binding the beta-amyloid generated by the hybridoma cell strain, and applications of the monoclonal antibody and the monoclonal antibody in detection, diagnosis and other aspects, such as application in Alzheimer's disease diagnosis. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the scope of the invention. Those skilled in the art can implement and use the invention by making modifications, or appropriate alterations and combinations, of the methods and applications described herein without departing from the spirit, scope, and content of the invention.

In order to make those skilled in the art better understand the technical solution of the present invention, the following detailed description of the present invention is provided with reference to the embodiments.

Examples

Example 1 materials and methods

1.1 reagents and instruments

1.1.1 cell culture

1.1.2 ELISA detection

Name(s)	Manufacturer of the product
		Goat anti-mouse IgG (H + L)/HRP	BEIJING BIOSYNTHESIS BIOTECHNOLOGY Co.,Ltd.
ELISA enzyme linked plate	Beijing Zhongsheng Aobang Biotechnology Co.,Ltd.
		TMB color development liquid	BEIJING BIOSYNTHESIS BIOTECHNOLOGY Co.,Ltd.
Enzyme mark instrument	MD

1.2 animals

BalB/C	Female
		The week of the year	6W-8W
Manufacturer of the product	China Institute for food and drug control

EXAMPLE 2 preparation of monoclonal antibodies

2.1 animal immunization

Emulsifying beta-amyloid (Abeta 1-42 subtype) immunogen and adjuvant according to the volume ratio of 1:1, and performing multi-point immunization injection subcutaneously on Balb/c mice (10 mice), wherein the immunization scheme is shown in Table 1:

TABLE 1

2.2 potency assay

The ascites of 10 immunized mice are respectively diluted into different concentrations by physiological saline, and the titer is measured by an enzyme-linked immunosorbent assay (ELISA) method, which comprises the following specific steps:

1. coating: diluting beta-amyloid (Abeta 1-42 subtype) immunogen with coating buffer PBS, adding the diluted immunogen into an ELISA (enzyme-linked immunosorbent assay) enzyme-linked plate at 0.1 mu g/hole, and standing overnight at 4 ℃;

2. and (3) sealing: washing with physiological saline for 3 times, adding confining liquid, incubating at 37 deg.C for 1.5 hr, and adding blocking liquid at 200 μ l/hole;

3. adding 100 μ l of sample to be tested into the microporous plate, incubating for 45 min at 37 ℃, washing the plate for 3 times, and drying;

4. adding 100 μ l enzyme-labeled antibody, diluting with PBS 5000 times, incubating at 37 deg.C for 45 min, washing plate for 3 times, and drying;

5. adding 100 mul of TMB color development solution, reacting for 5 min at room temperature, adding stop solution, and reading on an enzyme-linked immunosorbent assay (ELISA) instrument;

the negative control was physiological saline. The ELISA titer test results are shown in Table 2:

TABLE 2

Dilution ratio	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10
											1:1000	2.509	2.216	1.984	2.226	2.26	2.51	1.543	1.332	1.607	1.843
1:2000	2.242	1.649	1.618	1.971	2.019	2.136	1.118	0.889	1.453	1.388
											1:4000	1.908	1.237	1.077	1.593	1.507	1.457	0.88	0.722	1.054	1.076
1:8000	1.375	0.97	0.682	1.24	1.25	1.275	0.553	0.419	0.7	0.793
											1:16000	0.91	0.606	0.469	0.873	0.759	0.885	0.348	0.256	0.47	0.523
1:32000	0.589	0.373	0.302	0.526	0.543	0.498	0.205	0.168	0.279	0.32
											1:64000	0.387	0.247	0.211	0.385	0.368	0.363	0.146	0.13	0.227	0.222
Negative control	0.072	0.068	0.063	0.069	0.077	0.072	0.068	0.062	0.069	0.077

2.3 cell fusion and selection

And selecting splenocytes of a #1 Balb/C mouse with the best immune response to perform cell fusion with SP2/0 mouse myeloma cells, using beta-amyloid (Abeta 1-42 subtype) as a detection antigen package plate, and obtaining a positive hybridoma cell strain 6C8-1B9 which stably secretes specific antibodies through multiple screening and multiple stability tests. The cell line 6C8-1B9 was deposited in China general microbiological culture Collection center (CGMCC) by Beijing first Biochemical pharmaceutical Co., Ltd in 2022, 2.17.s.: the western road No. 1 hospital, north cheng chaoyang district, No. 3, in beijing, china, the zip code: 100101 with the preservation number of CGMCC number 45042, and is named as Balb/c mouse hybridoma cells in classification.

2.4 amplification culture

Culturing the positive cell strain 6C8-1B9 in a T75 culture bottle, freezing and preserving seeds and preparing ascites;

the ascites preparation procedure is as follows: sensitizing a mouse by using liquid paraffin, simultaneously culturing hybridoma cells, performing mouse intraperitoneal injection on the cultured hybridoma cells, observing the growth state of ascites of the mouse, and collecting the ascites in time;

the generation marking-limited dilution 6-hole culture is considered as the first generation, one generation is added every passage, the screened cells are expanded into a T75 culture bottle for culture, the cells are frozen and preserved in 80 percent, and the cells are frozen and preserved for 3 times;

freezing and storing liquid: 90% FBS +10% DMSO.

2.5 cell cryopreservation and Resuscitation

2.5.1 cell recovery:

culture medium: 10% FBS +1% PS + DMEM (high sugar type)

1. Preparing a 15 ml sterile centrifuge tube in a safety cabinet, and adding 9 ml of a basic culture medium for later use;

2. rapidly thawing the frozen cells in a 37 ℃ water bath;

3. transferring the thawed cells into a 15 ml centrifuge tube by using a 1 ml gun in a biological safety cabinet, and centrifuging for 5 min at 1000 r/min;

4. the supernatant was discarded, and the pellet was resuspended in complete medium and cultured in a T75 flask.

2.5.2 cell cryopreservation

Freezing and storing liquid: 6:3:1(60% FBS +30% basal medium +10% DMSO) or 90% FBS +10% DMSO;

1. cells (with round and bright state and 80% -90% cell confluence degree) cultured by a T75 culture bottle are placed in a 50 ml sterile centrifuge tube at 800 r/min-1000 r/min for centrifugation for 5 min;

2. discarding the supernatant, taking 3 ml of the frozen stock solution for quick suspension, subpackaging into 2 frozen tubes, placing into a gradient frozen stock box, and storing in a refrigerator at-80 ℃;

3. the next day from-80 ℃ freezer to liquid nitrogen.

2.6 antibody purification

And purifying the selected immune ascites by Protein G affinity chromatography to obtain the monoclonal antibody. Before purification, a preliminary test was performed using ascites dilution, and the negative control was normal saline. The ELISA test result shows that the ascites has the EC with pM grade ₅₀ The value is obtained.

2.7 ELISA detection of purified antibody

1. Coating the ELISA plate with antigen (bs-0107P), 2. mu.g/ml, 0.2. mu.g/well;

2. the purified antibody was diluted in the following proportions: 1:500, 1:2000, 1:8000, 1:32000, 1:128000, 1:512000, and 1: 2048000;

3. the secondary antibody is diluted with goat anti-mouse IgG labeled by horseradish peroxidase at a ratio of 1: 5000;

4. the color developing agent is tetramethyl benzidine;

5. the detection wavelength is as follows: at 450nm, the OD value was measured.

The negative control was physiological saline. The results of ELISA testing are shown in FIG. 1 and Table 3, and the EC of the monoclonal antibody produced by hybridoma cell line 6C8-1B9 ₅₀ The value was 30.58 pM.

TABLE 3

Example 3 mouse monoclonal antibody subtype detection assay

3.1 Experimental materials

Mouse antibody subtype rapid detection card: CAT # THJ-ISO-M8a-10/20, Beijing Taihe Biochemical research and development Co., Ltd;

6C8-1B9 hybridoma cell purification antibody: 2 mg/mL, Beijing Boaosen Biotech, Inc.

3.2 principle of the experiment

The subtype of the mouse antibody is rapidly detected by adopting a colloidal gold immunochromatography technology, the color is rapidly developed within 5 minutes, and the subtypes of a heavy chain constant region and a light chain constant region of the mouse antibody can be detected.

3.3 Experimental procedures

1) Opening the detection card package, and horizontally placing the detection card package on an experiment table;

2) diluting the antibody to be detected to a desired concentration (0.35. mu.g/ml) using purified water;

3) sucking 80-100 mul of sample by using a micropipettor, and dripping the sample into a sample adding hole;

4) standing for 5-10 min to read the result;

the results showed that the heavy chain constant region of the monoclonal antibody produced by the 6C8-1B9 hybridoma cell was of the IgG2B subtype and the light chain constant region was of the kappa subtype (FIG. 2).

It will be understood that, although the invention herein has been described in the foregoing specific forms, these inventions are not to be limited to the particulars described in these specific forms. It will be obvious to those skilled in the art that various equivalent changes may be made in the technical features of the invention involved therein without departing from the spirit of the invention described in the present application, and these changes should be construed as being within the scope of the invention.

Claims

1. A hybridoma cell strain which can generate a monoclonal antibody specifically combined with beta-amyloid and is preserved with a preservation number of CGMCC number 45042.

2. The hybridoma cell strain of claim 1, wherein the monoclonal antibody specifically binds to human β -amyloid A β 1-42 subtype.

3. The hybridoma cell strain of claim 1, wherein the monoclonal antibody comprises a heavy chain constant region of the IgG2b subtype; and

the monoclonal antibody comprises a light chain constant region of the kappa subtype.

4. The hybridoma cell line of claim 1, wherein the EC of said monoclonal antibody ₅₀ The value does not exceed 100 pM.

5. A monoclonal antibody specifically binding to amyloid beta produced by the hybridoma cell line of any one of claims 1 to 4.

6. A method for producing the monoclonal antibody of claim 5, which comprises culturing the hybridoma cell strain of any one of claims 1 to 4.

7. The method of claim 6, further comprising the step of purifying the monoclonal antibody.

8. Use of the hybridoma cell line of any one of claims 1 to 4 or the monoclonal antibody of claim 5 for the preparation of a product for detecting amyloid beta.